Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

Abstract

The influence of vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) on prognosis and the relationship between VEGF expression and MVD in ovarian carcinoma are not well defined. We studied VEGF expression in parallel with MVD by immunohistochemistry in 94 ovarian tumours (64 malignant, 13 borderline, and 17 benign) and correlated the results with the clinicopathologic prognostic factors of the disease to clarify their significance in this disease. Assessment of VEGF mRNA isoforms by RT-PCR was also performed. Of the malignant, borderline, and benign ovarian tumours respectively, two (3%), four (31%) and 16 (94%) were negative, 31 (48%), seven (54%) and one (6%) had low expressions, and 31 (48%), two (15%) and none (0%) had high expressions of VEGF. There were significant associations between the VEGF expression and disease stage (P= 0.002), histologic grade (P= 0.0004), and patient outcome (P= 0.0002). MVD did not correlate significantly with the clinicopathologic parameters. Likewise, no correlation was found between MVD and VEGF expression. The survival of patients with high VEGF expression was significantly worse than that of patients with low and negative VEGF expression (P = 0.0004). Multivariate analysis revealed that disease stage and VEGF expression were significant and independent prognostic indicators of overall survival time (P = 0.008 and P = 0.006 respectively). These findings suggest that in conjunction with the established clinicopathologic prognostic parameters of ovarian carcinoma, VEGF expression may enhance the predictability of patients at high risk for tumour progression who are potential candidates for further aggressive therapy.

References 32

1. 1.

   Abu-Jawdeh G. M., Faix J. D., Niloff J., Tognazzi K., Manseau E., Dvorak H. F., Brown L. F. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest. 1996;74(6):1105-1115.

   Not in our library

2. 2.

   Boocock C. A., Charnock-Jones D. S., Sharkey A. M., McLaren J., Barker P. J., Wright K. A., Twentyman P. R., Smith S. K. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995;87(7):506-516.

   Not in our library10.1093/jnci/87.7.506

3. 3.

   Ferrara N., Henzel W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851-858.

   Not in our library10.1016/0006-291x(89)92678-8

4. 4.

   Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat. 1995;36(2):127-137.

   Not in our library10.1007/bf00666035

5. 5.

   Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol. 1999;237:1-30.

   Not in our library10.1007/978-3-642-59953-8_1

6. 6.

   Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res. 1986;46(2):467-473.

   Not in our library

7. 7.

   Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4-6.

   Not in our library10.1093/jnci/82.1.4

8. 8.

   Fujimoto J., Sakaguchi H., Hirose R., Ichigo S., Tamaya T. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer. 1998;83(12):2528-2533.

   Not in our library10.1002/(sici)1097-0142(19981215)83:12<2528::aid-cncr18>3.0.co;2-n

9. 9.

   Garzetti G. G., Ciavattini A., Lucarini G., Pugnaloni A., De Nictolis M., Amati S., Romanini C., Biagini G. Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer. 1999;85(10):2219-2225.

   Not in our library10.1002/(sici)1097-0142(19990515)85:10<2219::aid-cncr17>3.0.co;2-s

10. 10.

    Garzetti G. G., Ciavattini A., Lucarini G., Pugnaloni A., De Nictolis M., Amati S., Romanini C., Biagini G. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining. Gynecol Oncol. 1999;73(3):396-401.

    Not in our library10.1006/gyno.1999.5377

11. 11.

    Ghazizadeh M., Ogawa H., Sasaki Y., Araki T., Aihara K. Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: relationship with histopathology and prognosis. Hum Pathol. 1997;28(8):960-966.

    Not in our library10.1016/s0046-8177(97)90012-5

12. 12.

    Hartenbach E. M., Olson T. A., Goswitz J. J., Mohanraj D., Twiggs L. B., Carson L. F., Ramakrishnan S. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 1997;121(2):169-175.

    Not in our library10.1016/s0304-3835(97)00350-9

13. 13.

    Hazelton D., Nicosia R. F., Nicosia S. V. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res. 1999;5(4):823-829.

    Not in our library

14. 14.

    Hollingsworth H. C., Kohn E. C., Steinberg S. M., Rothenberg M. L., Merino M. J. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995;147(1):33-41.

    Not in our library

15. 15.

    Kamat B. R., Brown L. F., Manseau E. J., Senger D. R., Dvorak H. F. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol. 1995;146(1):157-165.

    Not in our library

16. 16.

    Keck P. J., Hauser S. D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246(4935):1309-1312.

    Not in our library10.1126/science.2479987

17. 17.

    Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-844.

    Not in our library10.1038/362841a0

18. 18.

    Kraft A., Weindel K., Ochs A., Marth C., Zmija J., Schumacher P., Unger C., Marmé D., Gastl G. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85(1):178-187.

    Not in our library

19. 19.

    Millauer B., Shawver L. K., Plate K. H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994;367(6463):576-579.

    Not in our library10.1038/367576a0

20. 20.

    Nakanishi Y., Kodama J., Yoshinouchi M., Tokumo K., Kamimura S., Okuda H., Kudo T. The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol. 1997;16(3):256-262.

    Not in our library10.1097/00004347-199707000-00011

21. 21.

    Olson T. A., Mohanraj D., Carson L. F., Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994;54(1):276-280.

    Not in our library

22. 22.

    Orre M., Lotfi-Miri M., Mamers P., Rogers P. A. Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary. Br J Cancer. 1998;77(12):2204-2209.

    Not in our library10.1038/bjc.1998.367

23. 23.

    Orre M., Rogers P. A. VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary. Int J Cancer. 1999;84(2):101-108.

    Not in our library10.1002/(sici)1097-0215(19990420)84:2<101::aid-ijc2>3.0.co;2-5

24. 24.

    Paley P. J., Staskus K. A., Gebhard K., Mohanraj D., Twiggs L. B., Carson L. F., Ramakrishnan S. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997;80(1):98-106.

    Not in our library10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a

25. 25.

    Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Harvey V. S., Dvorak H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983-985.

    Not in our library10.1126/science.6823562

26. 26.

    Sowter H. M., Corps A. N., Evans A. L., Clark D. E., Charnock-Jones D. S., Smith S. K. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest. 1997;77(6):607-614.

    Not in our library

27. 27.

    Tempfer C., Obermair A., Hefler L., Haeusler G., Gitsch G., Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol. 1998;92(3):360-363.

    Not in our library10.1016/s0029-7844(98)00190-2

28. 28.

    Weidner N., Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol. 1996;167-190.

    Not in our library

29. 29.

    Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.

    Not in our library10.1056/nejm199101033240101

30. 30.
    Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels · 1997

    No notice
31. 31.

    de Vries C., Escobedo J. A., Ueno H., Houck K., Ferrara N., Williams L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255(5047):989-991.

    Not in our library10.1126/science.1312256

32. 32.

    de Vries C., Escobedo J. A., Ueno H., Houck K., Ferrara N., Williams L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255(5047):989-991.

    Not in our library10.1126/science.1312256

Cited by papers we hold 2

• Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer · 2019
  Not checked
• Bevacizumab and ovarian cancer · 2013
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.